Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Allergan Inc Raises Low End Of Prior FY 2013 Guidance; Issues Q4 2013 Guidance; EPS Guidance Below Analysts' Estimates


Tuesday, 29 Oct 2013 09:00am EDT 

Allergan Inc announced that for fiscal 2013, it expects total product net sales between $6.125 billion and $6.200 billion and Non-GAAP diluted earnings per share (EPS) attributable to stockholders from continuing operations between $4.74 and $4.76. For the fourth quarter of 2013, it expects total product net sales between $1.585 billion and $1.660 billion and Non-GAAP diluted earnings per share (EPS) attributable to stockholders from continuing operations between $1.31 and $1.33. According to I/B/E/S Estimates, analysts are expecting the Company to report EPS of $4.76 for fiscal 2013; revenue of $1.625 billion and EPS of $1.35 for the fourth quarter of 2013. 

Company Quote

166.61
0.96 +0.58%
24 Apr 2014